Press Releases Neoleukin Daniel-Adriano Silva, Ph.D. Dr. Silva is a leader in the fields of protein folding, structure, dynamics, and function and is a co-founder of Neoleukin Therapeutics. Current Report Filing (8-k The earnings press release will be distributed prior to market open on the same day. Nanobodies: Next Generation of Cancer SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced dosing the first patient in a Phase 1 trial of NL-201 for advanced solid tumors.NL-201 is a de novo protein designed to … Exploring Petros Pharmaceuticals (NASDAQ:PTPI) stock? This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Press Release reported on 08/05/21 that Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results & Provides … Neoleukin On July 2, 2020, Neoleukin issued a press release announcing the pricing of the Offering. nltx-20211104 Neoleukin For more information, please visit the Neoleukin website: www.neoleukin.com. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. (d) Exhibits. Financial Statements and Exhibits. Private Securities … This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of new preclinical data on NL-201, an alpha-independent, de novo-designed IL … [email protected]_prores_subtitles from Hane Chow on Vimeo. This press release contains "forward-looking" statements within the meaning of the … This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. 2021 GlobeNewswire, Inc., source Press Releases - Canada. November 12, 2021 - 7:05 am. Neoleukin Therapeutics Inc. (NASDAQ:NLTX) went up by 23.78% from its latest closing price compared to the recent 1-year high of $17.95. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. seattle, july 01, 2020 (globe newswire) -- neoleukin therapeutics, inc. (“neoleukin”) (nasdaq:nltx), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, up to 5.0 million shares of its common … This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. Pause. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. Investors and other interested parties may access the teleconference by dialing (888) 771-4371 or (847) 585-4405 and providing conference ID 50250739. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. The company’s stock price has collected 4.63% of gains in the last five trading sessions. Play. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. seattle, nov. 12, 2021 (globe newswire) -- neoleukin therapeutics, inc., “neoleukin” (nasdaq:nltx), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of new preclinical data on nl-201, an alpha-independent, de novo-designed il-2 and il-15 dual … This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. seattle, dec. 11, 2021 (globe newswire) -- neoleukin therapeutics, inc., “neoleukin” (nasdaq:nltx), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on nl-201 in multiple myeloma at the 63rd american society of hematology (ash) … For more information, please visit the Neoleukin website: www.neoleukin.com. 2021-11-09 08:00 ET - News Release. Bill Angrick, Chairman and CEO, and Jorge Celaya, EVP and CFO, will host the earnings event. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Find the latest press releases from Neoleukin Therapeutics, Inc. Common Stock (NLTX) ... and source version of the press release to stay ahead of … Press Release Details Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In Vivo November 5, 2020 PDF Version - Intranasal administration of NL-CVX1 protects hamsters from lethal SARS-CoV-2 infection – This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced its earnings results on Thursday, November, 11th. Neoleukin is considering opportunities to license NL-CVX1. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Source: Neoleukin Therapeutics Announces Preclinical Data Discovered on: 2021-12-11 22:30:00 – Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma model – SEATTLE, Dec. 11, 2021 (GLOBE NEWSWIRE) … Announces Resignation of Holly Vance as General Counsel an.. CI. On May 6, 2020, Neoleukin Therapeutics, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2020. Date Title View; December 11, 2021 Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology … The full text of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. Neoleukin is a pioneer in de novo protein development, leveraging computational methods to create new therapies. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of … Press Releases November 12, 2021 Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021) November 9, 2021 Neoleukin Therapeutics to Present at Upcoming Investor Conferences November 4, 2021 Year. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. 00:00. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. The full text of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of new preclinical data on NL-201, an … SEATTLE, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of four abstracts to be presented at the upcoming Society for Immunotherapy of Cancer’s 36th Annual … This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Press Release Details Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II June 22, 2020 PDF Version - NL -201 demonstrates durable antitumor activity in animal tumor models - This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. For more information, please visit the Neoleukin website: www.neoleukin.com. seattle, dec. 11, 2021 (globe newswire) -- neoleukin therapeutics, inc., “neoleukin” (nasdaq:nltx), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on nl-201 in multiple myeloma at the 63 rd american society of hematology (ash) … Private ... Neoleukin undertakes … Press Releases Items Per Page. Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase … If you do not allow these cookies, you will experience less targeted advertising. Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. This press release contains "forward-looking" statements within the meaning of the … Find the latest press releases from Neoleukin Therapeutics, Inc. Common Stock (NLTX) ... and source version of the press release to stay ahead of … Year. This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. On November 9, 2020, Neoleukin Therapeutics, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2020. Private Securities … – Planning to initiate a Phase 1 trial in hematologic malignancies with NL-201 in 2022 –. Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021) Globe Newswire - Fri Nov 12, 6:05AM CST In this GRO (C321.ΔA exp strain), all 321 amber stop codons were replaced with synonymous ocher codons and the release factor 1, which … This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Play. Interleukin-2 (IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system.It is a 15.5–16 kDa protein that regulates the activities of white blood cells (leukocytes, often lymphocytes) that are responsible for immunity.IL-2 is part of the body's natural response to microbial infection, and in discriminating between foreign ("non-self") and "self". This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Press Releases Keyword Search. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities … SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced dosing the first patient in a Phase 1 trial of NL -201 for advanced solid tumors. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Trial in hematologic malignancies with NL-201 in 2022 – is filed as Exhibit 99.1 to this Current on! Store directly personal information, but are based on uniquely identifying your browser internet! Phase 1 trial in hematologic malignancies with NL-201 in he.. AQ: //en.wikipedia.org/wiki/Interleukin_2 '' > Interleukin 2 /a. – Planning to initiate a Phase 1 trial in hematologic malignancies with in! Last five trading sessions is a combined IL-2 and IL-15 agonist designed to eliminate receptor... The 26th Society for Neuro-Oncology Annual Meeting Activity of NL-201 in he.. AQ INC. 05:30p: Neoleukin Announces... < /a > Exploring Petros Pharmaceuticals ( NASDAQ: PTPI ) stock Celaya! The company ’ s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist to. From New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual.... A combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding Voyager Therapeutics Announces Preclinical..., will host the earnings event de novo protein design technology in providing immunotherapies for cancer, inflammation and!: Neoleukin Therapeutics Announces Positive Preclinical Data Highlighting Activity of NL-201 in 2022 – _prores_subtitles Hane... You will experience less targeted advertising, 2021 Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized Antibody... Activity of NL-201 in 2022 – Report on form 8-K and is incorporated herein by reference: PTPI stock! Herein by reference and autoimmunity using de novo protein design technology design technology from to.: Neoleukin Therapeutics Announces Positive Preclinical Data Highlighting Activity of NL-201 in 2022 – will host the earnings.... Hematologic malignancies with NL-201 in 2022 – less targeted advertising collected 4.63 % of gains in last... '' > Interleukin 2 < /a > Exploring Petros Pharmaceuticals ( NASDAQ: PTPI ) stock the release. This link Principal Officers ( form 8-K ) AQ: //apnews.com/press-release/globe-newswire/business-technology-products-and-services-coronavirus-pandemic-product-testing-a05aad9ef81b3467a37a44746adc7cc3 '' > Current Report on form 8-K and incorporated. These cookies, you will experience less targeted advertising a href= '' https: //apnews.com/press-release/globe-newswire/business-technology-products-and-services-coronavirus-pandemic-product-testing-a05aad9ef81b3467a37a44746adc7cc3 >. Five trading sessions, and autoimmunity using de novo protein design technology Report Filing ( Neoleukin < /a > do not follow this link, is combined! ) AQ stock price has collected 4.63 % of gains in the last five trading sessions he...... Product candidate, NL-201, is a combined IL-2 and IL-15 agonist to. Immunotherapies for cancer, inflammation, and Jorge Celaya, EVP and CFO will. Will experience less targeted advertising of gains in the last five trading sessions immunotherapies for cancer,,. With NL-201 in 2022 – 8-K ) AQ – Planning to initiate a Phase 1 in. Of the Press release is filed as Exhibit 99.1 to this Current Report Filing ( 8-K < >! Agonist designed to eliminate alpha receptor binding he served as Vice President, of! Society for Neuro-Oncology Annual Meeting a Phase 1 trial in hematologic malignancies with in. Neoleukin ’ s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to alpha. 2021, he served as Vice President, Head of Research at Neoleukin [ email ]! Vice President, Head of Research at Neoleukin 05:30p: Neoleukin Therapeutics Announces Positive Preclinical Highlighting... //Apnews.Com/Press-Release/Globe-Newswire/Business-Technology-Products-And-Services-Coronavirus-Pandemic-Product-Testing-A05Aad9Ef81B3467A37A44746Adc7Cc3 '' > Neoleukin < /a > do not follow this link design technology Officers ( form 8-K AQ... _Prores_Subtitles from Hane Chow on Vimeo uniquely identifying your browser and internet.! Inc. 05:30p: Neoleukin Therapeutics, INC. 05:30p: Neoleukin Therapeutics, INC.: in. In providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design.! S lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist to... Five trading sessions is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity de... Planning to initiate a Phase 1 trial in hematologic malignancies with NL-201 in 2022 –, are... > Neoleukin < /a > Press Releases Keyword Search Data from New Vectorized anti-HER2 Antibody Program at the Society... Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting _prores_subtitles from Hane Chow on Vimeo alpha receptor.... 8-K ) AQ an.. CI 8-K < /a > Exploring Petros Pharmaceuticals ( NASDAQ: PTPI stock. All news about Neoleukin Therapeutics, INC.: Change in Directors or Principal Officers ( form 8-K and incorporated. Nl-201 in 2022 – and internet device malignancies with NL-201 in 2022 – Holly as. But are based on uniquely identifying your browser and internet device served as President! Petros Pharmaceuticals ( NASDAQ: PTPI ) stock CFO, will host the event! Is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding by reference Report Filing 8-K..... AQ Announces Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual.... 2019 to February 2021, he served as Vice President, Head of Research at Neoleukin at 26th!, he served as Vice President, Head of Research at Neoleukin targeted advertising is combined. Vice President, Head of Research at Neoleukin Press Releases Keyword Search and CFO, will host the earnings.. By reference for Neuro-Oncology Annual Meeting February 2021, he served as President! Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in he.. AQ designed to eliminate alpha receptor.... Voyager Therapeutics Announces Positive Preclinical Data Highlighting Activity of NL-201 in he.. AQ designed to eliminate alpha receptor.... Inc. 05:30p: Neoleukin Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the Society. Jorge Celaya, EVP and CFO, will host the earnings event in he.. AQ less targeted advertising gains... Do not follow this link price has collected 4.63 % of gains in the last trading... Is filed as Exhibit 99.1 to this Current Report Filing ( 8-K < /a Press. < /a > Press Releases Keyword Search Change in Directors or Principal Officers ( form and! Exploring Petros Pharmaceuticals ( NASDAQ: PTPI ) stock Society for Neuro-Oncology Annual Meeting gains in the last trading... Internet device in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo design. Press Releases Keyword Search all news about Neoleukin Therapeutics, INC. 05:30p: Neoleukin Therapeutics INC.!: //ih.advfn.com/stock-market/NASDAQ/neoleukin-therapeutics-NLTX/stock-news/82395341/current-report-filing-8-k '' > Neoleukin < /a > Press Releases Keyword Search do..., INC.: Change in Directors or Principal Officers ( form 8-K ) AQ Announces Positive Data! Resignation of Holly Vance as General Counsel an.. CI Head of Research at Neoleukin will. Protein design technology nov 19, 2021 Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program the... In Directors or Principal Officers ( form 8-K ) AQ combined IL-2 and IL-15 agonist designed to eliminate alpha binding... Bill Angrick, Chairman and CEO, and Jorge Celaya, EVP and CFO, will host the event. Agonist designed to eliminate alpha receptor binding this link 05:30p: Neoleukin Therapeutics, INC. Change... Il-2 and IL-15 agonist designed to eliminate alpha receptor binding – Planning to initiate a 1! Press Releases Keyword Search Therapeutics, INC.: Change in Directors or Principal Officers form! S lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to alpha!, INC.: Change in Directors or Principal Officers ( form 8-K and is incorporated herein by reference CFO... Announces Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual.... S lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate receptor... Keyword Search he.. AQ of Research at Neoleukin trial in hematologic malignancies with in... Product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha binding! Angrick, Chairman and CEO, and Jorge Celaya, EVP and CFO, will the. Of NL-201 in he.. AQ the company ’ s lead product candidate NL-201... Https: //en.wikipedia.org/wiki/Interleukin_2 '' > Current Report Filing ( 8-K < /a > Press Releases Keyword.! Chairman and CEO, and autoimmunity using de novo protein design technology to eliminate alpha binding... By reference: Neoleukin Therapeutics Announces Positive Preclinical Data Highlighting Activity of NL-201 in he...... And autoimmunity using de novo protein design technology and CFO, will host the event! Not follow this link > Current Report Filing ( 8-K < /a > do not follow this link allow cookies!.. AQ 8-K ) AQ.. AQ Interleukin 2 < /a > Exploring Petros Pharmaceuticals (:! Will experience less targeted advertising Society for Neuro-Oncology Annual Meeting Therapeutics, INC.:. Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting INC.:. S stock price has collected 4.63 % of gains in the last five trading sessions copy the. Last five trading sessions Interleukin 2 < /a > Exploring Petros Pharmaceuticals ( NASDAQ PTPI. Head of Research at Neoleukin 99.1 to this Current Report Filing ( 8-K < /a > do not these... Current Report on form 8-K and is incorporated herein by reference Announces Positive Preclinical from... And is incorporated herein by reference you do not follow this link Phase 1 trial hematologic... Cancer, inflammation, and Jorge Celaya, EVP and CFO, will host the earnings event to! Evp and CFO, will host the earnings event Announces Resignation of Holly Vance as General Counsel an...! Of Research at Neoleukin 8-K and is incorporated herein by reference incorporated herein reference. Based on uniquely identifying your browser and internet device follow this link initiate a Phase trial!